179 search results for: Pathophysiology
How Type 2 Inflammation Drives Eosinophils in Asthma
Explore how type 2 inflammation drives the production of eosinophils in severe asthma.
Exploring the Mechanisms of FeNO Production in the Lungs
Explore how type 2 inflammation drives the production of FeNO in severe asthma
Understanding the Contribution of IL-4 in the Development of Fibrosis in Prurigo Nodularis
Professor Sarina Elmariah highlights the multifaceted role of IL-4 and IL-13 in driving dermal fibrosis in prurigo nodularis, which leads to persistent scarring and dyspigmentation that significantly contribute to patients' embarrassment, anxiety, depression, and self-esteem.
Beyond Itch: The Multifaceted Role of IL-4/IL-13 in the Pathogenesis of PN
Professor Sarina Elmariah describes how IL-4 and IL-13, key drivers of type 2 inflammation, uniquely contribute to manifestations of prurigo nodularis beyond itch.
ADVENT On Air | Many Faces of COPD: From Phenotypes to Endotypes
Drs Nicola Hanania and Francesca Polverino explore the Many Faces of COPD: From Phenotypes to Endotypes.
Clinical Manifestations Associated With Airway Remodeling in Asthma
Join Dr. Hanania to understand how to identify patients at risk of fixed airway obstruction in clinical settings.
Impact of Exacerbations in COPD
Dr. Stephanie Christenson discusses the association between COPD exacerbations and the increased risks of morbidity and mortality
Exacerbations Lead to Worsening Lung Function
Dr. Mario Castro discusses how COPD exacerbations can predict future exacerbations and lead to progressive lung function loss in COPD patients.
Pediatric Asthma Trajectory and Clinical Remission
Join Dr. Leonard Bacharier as he discusses the definition of clinical remission in pediatric asthma and how it can represent a potential target in pediatric asthma management
Both Clinical and Subclinical Disease Control Are Important to Achieve Disease Modification in AD
In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Dr. Eric Simpson explains how both clinical and subclinical disease control are critical for achieving true disease modification in atopic dermatitis, emphasizing the role of biomarkers in predicting long-term outcomes and guiding treatment decisions.
Navigating Complex Definitions: Early Intervention and Disease Modification in Atopic Dermatitis
Dr. Amy Paller discusses the evolving concepts of early intervention and disease modification in AD and describes potential biomarkers of subclinical control at EADV 2025.
KOL Video Interview – Dr Paula Luna
In this exclusive video interview, Dr Paula Luna discusses how disease modification can be defined in AD and how IgE may be used as a biomarker in AD.
